Aldosterone synthase inhibitors for treating chronic kidney disease
AssigneeBoehringer Ingelheim International GmbH
InventorsLisa V. CRONIN, Sibylle Jenny HAUSKE, Hartmut RUETTEN
Life of this patent
Estimating the term…
Abstract
The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I): and pharmaceutically acceptable salts thereof, wherein Cy, R1 and R2 are as defined herein. The invention further relates to the use of the compounds of formula (I) in combination with sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Claims8
A method for treating, preventing, and/or reducing the risk of chronic kidney disease progression, end stage kidney disease, renal death or cardiovascular death in adult chronic kidney disease CKD patients who are at high risk for disease progression, the method comprising administering to the patient compound 29A
- wherein compound 29A is administered once daily in an amount of 3 mg, 10 mg, or 20 mg.
Dependencies are inferred from the claim text.